Validity of composite end points in clinical trials
Víctor M. Montori(Mayo Clinic), Gaietà Permanyer-Miralda, Ignacio Ferreira‐González(Universitat Autònoma de Barcelona), Jason W. Busse(McMaster University), Valeria Pacheco‐Huergo(Institut Català de la Salut), Dianne Bryant(McMaster University), Jordi Alonso(Municipal Institute for Medical Research), Elie A. Akl(University at Buffalo, State University of New York), Antònia Domingo‐Salvany(Municipal Institute for Medical Research), Edward J. Mills(Canadian College of Naturopathic Medicine), Ping Wu(Canadian College of Naturopathic Medicine), Holger J. Schünemann(University at Buffalo, State University of New York), Roman Jaeschke(McMaster University), Gordon Guyatt(McMaster University)
Cited by 428Open Access
Abstract
Use of composite end points as the main outcome in randomised trials can hide wide differences in the individual measures. How should you apply the results to clinical practice?
Related Papers
No related papers found
Powered by citation graph analysis